Market Overview

UPDATE: Credit Suisse Initiates AbbVie at Neutral on Humira Dependence

Related ABBV
Lipocine Inc Halted: Feds Eye Safety, Efficacy Of Testosterone
US Stock Futures Drop Ahead Of Jobless Claims Report
IRS, Eh? Tim Hortons Deal Could Lower Burger King's Tax Bill (Fox Business)

Credit Suisse initiated AbbVie (NYSE: ABBV) with a Neutral rating and a $37.00 price target.

Credit Suisse noted, "AbbVie's cross-currents imply minimal stock movement from current price. Growth is modest with 2013-2020 sales and EPS CAGR at 2% and 3% respectively and only 20% revenue contribution from the pipeline by 2020. Humira contribution to ABBV is significant; contribution to sales '13-20 is at minimum 50%, and over 70% to profits. Positives: ~9% free cash flow yield, 4.3% dividend yield, 11.9x P/E (pharma 2013 average 13.9x), options on elagolix, ABT-199 for lymphoma & business development (BD). Negatives: overdependence on Humira and long-term competitive threat from orals and biosimilars, HCV franchise expectations already realistic."

AbbVie closed at $75.39 on Wednesday.

Latest Ratings for ABBV

DateFirmActionFromTo
Aug 2014Credit SuisseMaintainsOutperform
Jul 2014UBSUpgradesNeutralBuy
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Analyst Ratings

 

Related Articles (ABBV)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters